IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Status:	Completed
Conditions:	Blood Cancer, Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	12/31/2017
Start Date:	January 2012
End Date:	July 2016

A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

The purpose of this study is to test the safety and tolerability of IMGN529 in patients with
relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

Inclusion Criteria:

- Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal
zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell
lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL).

- Adequate organ function

- ECOG ≤ 2

- Recovered or stabilized from prior treatments.

Exclusion Criteria:

- Allogeneic stem cell transplantation

- Pregnant or lactating females

- Known central nervous system, meningeal or epidural disease including brain metastases

We found this trial at

sites

Memorial Sloan Kettering Cancer Center

1275 York Ave
New York, New York 10021

(212) 639-2000